Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research

Key Points

• Zacks Research downgraded Novavax from “strong buy” to “hold,” while broader analyst sentiment remains mixed. Five analysts rate the stock a buy, two a hold and three a sell; the consensus price target is $13.
• Novavax shares opened at $7.95, with a market capitalization of approximately $1.31 billion and a 52-week range of $6.20 to $11.97.
• The company reported a quarterly loss of $0.32 per share, better than the expected $0.38 loss, and revenue of $56.7 million versus estimates of $52.5 million. However, revenue declined 76.2% year over year and the company continued to report negative profitability metrics.

Novavax (NASDAQ:NVAX - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a research note issued on Thursday,Zacks.com reports.

A number of other research analysts have also issued reports on NVAX. B. Riley Financial reiterated a "buy" rating on shares of Novavax in a report on Thursday, April 9th. TD Cowen upped their price target on Novavax from $8.00 to $9.00 and gave the stock a "hold" rating in a report on Wednesday, May 6th. BTIG Research reaffirmed a "buy" rating and issued a $19.00 price target on shares of Novavax in a research report on Thursday, June 11th. Wall Street Zen cut Novavax from a "hold" rating to a "sell" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Novavax in a research report on Tuesday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $13.00.

Novavax Stock Up 2.7%

Shares of NVAX opened at $7.95 on Thursday. The company has a market cap of $1.31 billion, a P/E ratio of -5.23 and a beta of 2.46. Novavax has a fifty-two week low of $6.20 and a fifty-two week high of $11.97. The firm's 50 day moving average price is $8.72 and its 200 day moving average price is $8.97.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.06. The company had revenue of $56.70 million during the quarter, compared to analysts' expectations of $52.51 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The firm's revenue was down 76.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.62 EPS. Research analysts forecast that Novavax will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new stake in Novavax during the fourth quarter worth approximately $33,000. Quarry LP purchased a new position in Novavax in the third quarter valued at approximately $33,000. Duncker Streett & Co. Inc. increased its stake in Novavax by 917.3% in the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 3,825 shares during the last quarter. KBC Group NV raised its holdings in Novavax by 34.9% during the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 1,229 shares in the last quarter. Finally, State of Wyoming acquired a new stake in Novavax during the second quarter worth approximately $52,000. Hedge funds and other institutional investors own 53.04% of the company's stock.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a second-quarter adjusted loss of $0.32 per share, better than the expected $0.38 loss, while revenue of $56.7 million exceeded estimates of approximately $52.5 million. NVAX Q2 Earnings & Sales Beat Estimates, 2026 Sales Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 adjusted revenue framework to $235 million-$275 million from $230 million-$270 million and reduced combined GAAP research and development and selling, general and administrative expense guidance by $10 million at the midpoint. Novavax Raises 2026 Outlook After Q2 Beat
• Positive Sentiment: Novavax said completion of its manufacturing technology transfer to Sanofi is expected in mid-2027, potentially triggering a $75 million milestone payment. Sanofi also plans to advance discussions with regulators regarding timing for its Phase 3 COVID-19 and influenza combination-vaccine trial. Novavax Lifts Annual Revenue Forecast
• Neutral Sentiment: Novavax ended June with approximately $724 million in cash, cash equivalents, marketable securities and restricted cash. It also highlighted partner-led Matrix-M projects and plans to move its C. difficile vaccine program into clinical development as early as 2027. Novavax Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Revenue fell approximately 76% from the prior-year quarter to $56.7 million, product sales were only $19 million, and Novavax posted a $53 million net loss versus $107 million of net income a year earlier. The results underscore the company’s dependence on licensing revenue and milestone payments as vaccine demand wanes. Novavax Q2 Revenue Falls 76 Percent

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source